---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-23-000157"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:10:16.857114+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Praxis Q3 net loss $24.6M; starts Essential3 Phase 3 for ulixacaltamide

## Summary
- Cash $101.1M as of Sep 30, 2023, providing runway into Q1 2025.
- Initiated Essential3 Phase 3 program for ulixacaltamide in essential tremor; enrollment expected H1 2024.
- Completed Part 1 dosing of EMBRAVE study for elsunersen in SCN2A-DEE; seeking FDA guidance.
- R&D expenses $17.3M (down from $30.4M YoY); net loss $24.6M (down from $43.9M YoY).
- Expects topline results from PRAX-628 Phase 2a PPR study in Q4 2023.

## SEC filing metadata
- accession: 0001689548-23-000157
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954823000157/0001689548-23-000157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954823000157/prax-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-23-000157
- JSON: https://secwatch.observer/filing/0001689548-23-000157.json
- Plain text: https://secwatch.observer/filing/0001689548-23-000157.txt

## Key facts
- Earnings Releases
  Praxis Precision Medicines, Inc. reported the three months ended September 30, 2023 results: revenue $0.5 million, net income net loss of $24.6 million.
  - Period: the three months ended September 30, 2023
  - Revenue: $0.5 million
  - Net income: net loss of $24.6 million
  - Result: reported results
  source text: offerings of shares of Praxis’ common stock, partially offset by cash used in operations of $87.3 million during the nine months ended September 30, 2023. Praxis recognized $0.5 million in collaboration revenue during the three months ended September 30, 2023, related to its Option and License Agreement with UCB. Research and development expenses were $17.3
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689548/000168954823000157/0001689548-23-000157-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.